UCB、HS第3相BE HEARDの3年データをEHSFで発表へ──BIMZELXで炎症性病変完全消失40.1％ | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

UCB showcases three-year hidradenitis suppurativa data at EHSF; BIMZELX (bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

stellanews.life/technology/8...

#HidradenitisSuppurativa #HS #Bimekizumab #BIMZELX #EHSF #Phase3

HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis - PharmaTimes Bimekizumab offers fresh option for patients with chronic conditions

#HSE #HealthServiceExecutive #Ireland #hidradenitissuppurativa #HS #axialspondyloarthritis #axSpA #Bimekizumab #BIMZELEX #NadegeFeeser #Immunology #UCB #chronicdiseases #BrianKirby #Dermatology #HSpatients #phase3studies #clinicaltrial #BEHEARD1 #BEHEARD2 #moderatetosevereHS
zurl.co/NrDNa

SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not

#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...

Bimekizumab shows long-term efficacy in hidradenitis suppurativa - PharmaTimes UCB's BIMZELX reveals promising two-year data at EHSF 2025

#Bimekizumab #hidradenitissuppurativa #dermatology #UCB #UCBPharma #BIMZELX #EHSF2025 #BEHEARDtrials #HiSCR75responders #interleukin17Ainhibitor #IL17Ainhibitor #interleukin17Finhibitor #IL17Finhibitor #EuropeanHidradenitisSuppurativaFoundation #HSpatients
pharmatimes.com/news/bimekiz...

UCB Launches New 320 mg Single-Injection Option for BIMZELX in the U.S. UCB introduces a new 320 mg single-injection option for BIMZELX, enhancing treatment accessibility for chronic inflammation patients in the U.S.

UCB Launches New 320 mg Single-Injection Option for BIMZELX in the U.S. #United_States #Atlanta #UCB #BIMZELX #bimekizumab